Table 2 Clinical outcomes.

From: Preoperative cardiac troponin below the 99th-percentile upper reference limit and 30-day mortality after noncardiac surgery

 

Univariate analysis

Multivariate analysis

Propensity score matched analysis

LOD (N = 7958)

Mild elevation (N = 4457)

Unadjusted HR (95% CI)

p-Value

aAdjusted HR (95% CI)

p-Value

LOD (N = 3869)

Mild elevation (N = 3869)

Adjusted HR (95% CI)

p-Value

30-day mortality

164 (2.1)

178 (4.0)

1.96 (1.58–2.42)

 < 0.001

1.73 (1.39–2.16)

 < 0.001

101 (2.6)

161 (4.2)

1.61 (1.26–2.07)

 < 0.001

In-hospital mortality

220 (2.8)

246 (5.5)

1.59 (1.33–1.91)

 < 0.001

1.40 (1.16–1.69)

0.001

138 (3.6)

221 (5.7)

1.38 (1.12–1.71)

0.003

30-day peak hs-cTn I level, ng/L

242 (± 2862)

1179 (± 14,520)

   

 < 0.001

160 (± 2579)

688 (± 11,558)

 

0.01

MINS

644 (8.1)

840 (18.8)

   

 < 0.001

385 (10.0)

684 (17.7)

 

 < 0.001

  1. Data are presented as n (%) or mean (± standard deviation).
  2. 30-day peak hs-cTn I was available in 4086/7958 (51.3%) in LOD and 2529/4457 (56.7%) in mild elevation groups of the entire population.
  3. 30-day peak hs-cTn I was available in 2142/3869 (55.4%) in LOD and 2211/3869 (57.1%) in mild elevation groups of the propensity score matched population.
  4. Patients without elevated postoperative hs-cTn I were regarded as not having been diagnosed with MINS.
  5. LOD limit of detection; HR hazard ration; CI confidential interval; hs-cTn high-sensitivity cardiac troponin; MINS myocardial injury after noncardiac surgery.
  6. aCovariates include age, hypertension, diabetes, coronary artery disease, chronic kidney disease, previous stroke, arrhythmia, preoperative hemoglobin, antiplatelet agent, statin, beta-blocker, calcium channel blocker, renin–angiotensin–aldosterone system inhibitor, surgical risk, operation duration, and intraoperative inotropic use and red cell transfusion.
Back to article page